Telomere dysfunction is an early event in the development of prostate cancer and telomerase (TERT) activity is detectable in the majority of prostate cancers. Genetic variation in TERT and its regulatory elements may influence prostate carcinogenesis. MNS16A, a functional polymorphic tandem repeat minisatellite of TERT, has been studied in several malignancies. We determined MNS16A genotypes in an Austrian case-control study for the first time in the context of prostate cancer, comprising 1165 prostate cancer cases and 674 benign prostate hyperplasia controls with PCR. In addition to the five reported variable number of tandem repeats (VNTRs), we identified VNTR-212, a rare variant, for the first time in a European population. Multiple logistic regression analysis revealed no differences in genotype distribution between cases and controls. However, in stratified analysis, MNS16A VNTR-274 (OR = 0.25, 95% CI = 0.06-0.79, P = 0.016) and genotype 274/302 (OR = 0.13, 95% CI = 0.01-0.58, P = 0.005) were associated with a significantly decreased risk of prostate cancer in the age group >70 years. Our finding of a MNS16A genotype conferring a protective effect against prostate cancer in older men suggests a potential role of this polymorphism in prostate cancer susceptibility but demands to be validated in further studies.
Introduction
Prostate cancer (PC) is the second most common cancer in men worldwide with 900 000 newly diagnosed cases in 2008 (1) . Since the early 1990s, in Austria such as in many other developed countries, a strong increase in PC incidence rates due to widely used prostate-specific antigen (PSA) screening has been observed concomitant only with minute decline in PC mortality (2, 3) . Although a gradual decline in PC incidence was observed in Austria since 2003, this trend might largely be attributed to the earlier identification of PCs, including non-symptomatic indolent PCs. Overdiagnosis and overtreatment of clinically insignificant PCs are important issues in PC management (4) . Therefore, the identification of biomarkers for PC beside the established clinical markers such as PSA and Gleason score is required.
So far genome-wide association studies (GWAS) identified >40 PC susceptibility loci, the highest number in common cancers [recently reviewed in ref. (5)]. One of them is the telomerase reverse transcriptase (TERT) locus on chromosome 5p15.33 associated with several malignancies beside PC underlining the importance of this locus in tumorigenesis (5) (6) (7) .
Telomeres, the distal parts of eukaryotic chromosomes, are DNA-protein complexes that protect the chromosomal ends and consist of characteristic TTAGGG repeats in humans (8, 9) . Telomerase activity and maintenance of telomere length are hallmarks in human tumorigenesis. Telomere attrition, a consequence of cellular aging and the end-replication problem, can be counterbalanced by reactivation of telomerase enzymatic activity allowing cells to attain an unlimited proliferative potential. Dependent on a RNA component (TERC) and several other additional proteins and cofactors, the catalytic subunit of human telomerase (TERT) forms a multiprotein complex capable to add telomeric repeat sequence (TTAGGG) n to the ends of shortened chromosomes (10) . Telomerase activity is usually absent in somatic human cells but present in germline cells as well as in the majority of cancer cells and in vitro immortalised cells (11) (12) (13) . Telomere dysfunction is an early event in prostate carcinogenesis (14) and telomerase activity has been detected in the majority of PCs (15) .
MNS16A, a polymorphic tandem repeat minisatellite of TERT, located downstream of exon 16 of TERT gene and upstream in the putative promoter region of an antisense TERT transcript, was first identified by Wang et al. (2003) (16) . This minisatellite was shown to have promoter activity dependent on the number of tandem repeats. The structure of MNS16A was found to be characterised by two repeat elements forming a 23 bp, or when separated by a CAT trinucleotide insertion, a 26 bp core sequence. The sequence containing the CAT insert represents a transcription factor binding site for GATA-1. Four different variable number of tandem repeats (VNTRs) VNTR-243, VNTR-274, VNTR-302 and VNTR-333, named on the basis of their PCR fragment size, have been described (16) . Recently, we identified in our colorectal cancer study a further rare variant namely VNTR-364 (17) . Furthermore, in this study, we found the MNS16A VNTR-274 associated with a 2.7-fold increased colorectal cancer risk. This finding prompted us to investigate the influence of MNS16A VNTRs also on PC susceptibility in a hospital-based case-control study comprising 1165 PC patients and 674 controls with benign prostatic hyperplasia (BPH).
Materials and methods

Study population
In the ongoing Molecular Epidemiology Study of Prostate Cancer, 1839 participants, all of them Caucasians, were recruited from the departments of urology of three hospitals located in Vienna, Austria ('Sozialmedizinisches Zentrum Ost', 'Sozialmedizinisches Zentrum Süd' and the Medical University of Vienna). Cases (n = 1165) were patients with newly diagnosed, histologically verified PC. The diagnosis of PC was obtained by transrectal ultrasound (TRUS)-guided biopsies in all patients. The indication for PC was either a suspicious finding on digital rectal examination (DRE) and/or elevated serum PSA levels. Further diagnostic work-up in these patients included a nuclear bone scan. The control group (n = 674) consisted of men with lower urinary tract symptoms due to BPH/benign prostatic enlargement, recruited in Vienna. In controls, PC was excluded either clinically by negative DRE and negative serum PSA according to age-specific reference values or histologically by TRUSguided biopsies or transurethral resection of the prostate. Seventy-six percent of controls received a biopsy of the prostate. Written informed consent was obtained from all participants, and research protocols were approved by the institutional review boards.
Genotyping
Genomic DNA was purified from peripheral blood according to the QIAamp® DNA Blood Midi Spin Protocol (QIAGEN, Valencia, CA).
Twenty microlitre PCR reactions contained 40 ng genomic DNA, GeneAmp 1× PCR Buffer II, 1.5 mM MgCl 2 , 150 nM deoxyribonucleotide mix, 0.3 units AmpliTaq DNA Polymerase (Applied Biosystems, Foster City, CA) and 350 nM forward and reverse primers (VBC-BIOTECH Service, Vienna, Austria). MNS16A-specific primers were used as described by Wang et al. (16) . PCR amplification was performed on a 2720 Thermal Cycler (Applied Biosystems, Foster City, CA) with the following thermal profile: initial 5 min at 95°C; 35 cycles of 30 s at 95°C, 30 s at 65°C and 30 s at 72°C; with a final amplification step of 10 min at 72°C. MNS16A genotypes were determined by electrophoretical separation of PCR products in ethidium bromide-stained 2.5% agarose gels. Genotyping was performed blinded to case-control status and 15% of randomly chosen samples were re-genotyped for quality control. 
Statistical analysis
Genotypic counts of the control group were tested for Hardy-Weinberg equilibrium (HWE) using a chi-square test. Associations of MNS16A genotypes with risk of PC were estimated by computing odds ratios (ORs) and 95% confidence intervals (CIs) by logistic regression analysis with bias correction (R package logistf) (18) . The application of Firth's modified score procedure in logistic regression analysis corrects for the well-known problem of small sample bias (19) and provides estimates in case of complete separation. In the case at hand, complete separation occurs if a certain genotype is never observed neither in cases nor in controls.
Age and smoking status were considered as confounding factors. Smoking status (current, former, never) did not prove to be a significant factor for the development of PC, but all regression models contain a linear and quadratic age term. Calculations were performed for MNS16A VNTRs, MNS16A genotypes and the MNS16A SL classification system, frequently applied in literature. VNTR-212, VNTR-243 and VNTR-274 were classified as short (S) variants and VNTR-302, VNTR-333 and VNTR-364 were classified as long (L) variants. On basis of this classification, MNS16A genotypes were assigned to SS, SL or LL genotype groups. MNS16A VNTRs, genotypes and SL groups were included as factors with the most common VNTR or genotype as reference category. Stratified analysis was performed for three equally spaced age groups in order to investigate the hypothesis of age-specific genetic mechanisms in the development of PCs. The observed age at diagnosis of 99% of patients ranged between 40 and 85 years. Hence, age groups were defined as '<55 years', '55-70 years' and '>70 years', respectively. Further subgroup analysis was conducted dividing the case group into patients with aggressive and nonaggressive form of PC. Aggressiveness was defined on basis of Gleason score with Gleason scores ≥7 classified as aggressive and Gleason scores <7 as non-aggressive PC. Additionally, patients with Gleason score 7 and patients with Gleason score 8-10 were also considered as separate groups in stratified analysis. All tests were two-sided and P values <0.05 were considered statistically significant. All statistical analyses were performed with R version 2.15.0 (20) .
Results
Study population
Selected characteristics of the study population are presented in Table I . A total of 1839 participants of our Molecular Epidemiology of Prostate Cancer study was genotyped, including 1165 PC cases and 674 BPH controls. A total of 1137 cases and 650 controls were eligible for statistical analysis. Reduction in sample number was due to missing histology or covariate data.
The mean age of the case group (63.8 years) was significantly lower than the mean age of the control group (67.4 years, chisquare test, P < 2.1 × 10 -15 ). Smoking status did not significantly differ between case and control group (chi-square test, P = 0.469). Therefore, statistical models were not adjusted for smoking status.
Genotyping
In total, 1839 individuals were genotyped by standard PCR followed by electrophoretical separation. Genotyping was successful in 98.1% of all attempts. For quality control, 15% of the samples were randomly selected and re-genotyped. Table II . Controls were tested for Hardy-Weinberg equilibrium and showed no significant deviation (P = 0.49).
Logistic regression analysis revealed no significantly different distribution of MNS16A genotypes between PC cases and BPH controls (Table III) . Also the stratified analysis for Gleason score showed no significant differences in genotype distribution between PC cases with Gleason score <7 and BPH controls or between PC cases with Gleason score ≥7 and BPH controls. Furthermore, no differences in genotype distribution between PC cases with Gleason score 7 or >7 and BPH controls were observed (data not shown). However, for the age group >70 years, MNS16A VNTR-274 (OR = 0.25, 95% CI = 0.06-0.79, P = 0.016) and genotype 274/302 (OR = 0.13, 95% CI = 0.01-0.58, P = 0.005) were associated with a significantly decreased risk of PC (Table IV) .
Cloning
Sequence of VNTR-212 was confirmed by cloning and sequencing (Figure 1 ). VNTR-212 is the shortest known MNS16A VNTR and is by 31 bp shorter than VNTR-243. It can be described as a VNTR-243 that lost one of its tandem repeats separated by CAT trinucleotide and hence, of all six reported MNS16A VNTRs, carries the smallest number of GATA-1 transcription factor binding sites.
Discussion
MNS16A, a functional minisatellite of TERT, discovered in 2003 by Wang et al. (16) , has been investigated in several malignancies such as lung (16, (21) (22) (23) , breast (24), brain (25) (26) (27) and colorectal cancer (17) so far. This study is the first investigating genetic associations of MNS16A concerning PC. In our Austrian hospital-based case-control study comprising 1165 PC cases and 674 BPH controls, we observed no statistically significant association of MNS16A genotypes with risk of PC in the overall patient group. Stratified analysis for Gleason score was performed for aggressive PCs with Gleason score ≥7 and non-aggressive PCs with Gleason score <7. Because Gleason score 7 is a relatively heterogeneous histological group (28), we considered Gleason score 7 also as distinct group in statistical analyses. However, we observed no significant differences in genotype distribution of aggressive PCs and PCs with less aggressive form. However, in stratification for age, an association of MNS16A VNTR-274 (OR = 0.25, P = 0.016) and the MNS16A genotype 274/302 (OR = 0.13, P = 0.005) with a significantly decreased risk of PC was found in the age group >70 years suggesting a protective effect of VNTR-274 in older patients.
In accordance with our findings, Zhang et al. (29) recently reported a reduced risk of nasopharyngeal carcinoma (NPC) for carriers of VNTR-274 and 274/302 genotype. In this casecontrol study of 855 NPC patients and 1036 cancer-free controls, a reduced risk for SL (OR = 0.73, P = 0.037) and SS + SL (OR = 0.71, P = 0.025) genotype groups, containing the VNTR-274 variant allele, was observed when compared with the LL reference. Likewise, VNTR-274 (OR = 0.65, P = 0.058) and 274/302 genotype (OR = 0.64, P = 0.059) were associated with a lower risk of NPC when compared with the wild-type VNTR-302 and the wild-type genotype 302/302, respectively. The protective effect of reduced NPC risk conferred by SS + SL genotype was also more pronounced in older patients (≥45 years) and correlated with lower levels of TERT protein expression measured by immunohistochemistry assay in patients with SL genotypes. However, MNS16A genotypes did not correlate with progression of NPC.
In contrast, we previously reported a significant association of VNTR-274 with an increased risk of colorectal cancer Odds ratio with 95% confidence interval were adjusted for age. b P < 0.05 was considered significant (bold). Odds ratio with 95% confidence interval were adjusted for age. b P < 0.05 was considered significant. (17) . Also, in a Chinese breast cancer study (22) , 274/302 genotype was associated with a significantly increased risk of axillary lymph node metastasis. These findings suggest a potential relevance of VNTR-274 in susceptibility of these cancers but require further investigation. Although MNS16A studies concerning several malignancies have been conducted so far, the findings on clinical relevance regarding both risk and survival time are conflicting (recently discussed) (17) . Different study designs and selection bias as well as different genotyping methods and the differences of genotype frequencies between Asian and Caucasian populations may contribute to these discrepancies. Although the effect of MNS16A genotype on occurrence of disease is thought to act via modulating the repression of TERT expression, telomerase reactivation is gradually important or required in tumorigenesis of different cancers. Differences in molecular mechanisms in pathogenesis of different malignancies make it difficult to compare these findings. In prostate carcinogenesis, telomere dysfunction, a driver of genetic instability, is an early event in tumour development and telomerase activity is present in the majority of PCs [reviewed in ref. (30)]. It can be hypothesised that VNTR-274 by promoting TERT repression over time delays onset of PC and thereby confers a protective effect for patients carrying VNTR-274, or the 274/302 genotype, respectively. A strength of our study is the high quality control group, especially important in the context of PC, a malignancy highly frequent in older men. Controls were patients with histologically confirmed BPH, known to be free of PC or BPH patients where PC was clinically excluded by negative DRE and negative serum PSA. Selection bias was omitted by hospital-based recruitment of both cases and controls. However, a limitation was limited sample size in subgroup analysis and significant associations depended on a relatively small number of subjects with this genotype.
More than 40 PC susceptibility loci on various chromosomes have been identified by GWASs so far underlining the strong genetic influence on PC development. One of these loci is 5p15 harbouring variants rs2242652 of TERT (7), rs401681 and rs2736098 (6) . Besides single nucleotide polymorphisms, associations of a further polymorphic minisatellite of TERT, VNTR 2-2 nd with PC susceptibility were reported (31) . Genetic variants of TERT could predispose to cancer by causing telomere dysfunction leading to chromosomal instability and thereby driving tumour formation. It could be worth investigating whether these risk variants of TERT locus interact with MNS16A and other tandem repeat polymorphisms of the human telomerase gene (32) .
Because telomerase and telomeres play an important role in PC development, TERT expression and telomere length were discussed as markers for PC. Tumour telomere DNA content was associated with recurrence of PC, independent of age, Gleason score or lymph nodal status by Fordyce et al. (33) . Recently, the combined analysis of TERT expression with TMPRSS2-ERG [transmembrane protease, serine 2-v-ets erythroblastosis virus E26 oncogene homologue (avian)] fusion, one of the most common genetic rearrangements observed in PC, was suggested as predictor of biochemical recurrence of PC after radical prostatectomy (34) . Nevertheless, no single independent marker is likely to significantly augment the level of diagnostic and prognostic accuracy in the management of PC (35) . However, the combination of clinically established markers with markers recently identified by proteomic screens and DNA methylation profiling, presently being under validation, may substantially improve the present situation. Our report of TERT MNS16A genotype 274/302 and VNTR-274 conferring a protective effect against PC in older men indicates a potential role of this polymorphism in prostate carcinogenesis and demands to be validated in further studies.
